AI Drug Discovery

Hyper-C implementation

Welcome to the World of Hyper-C

Discovery

What is Hyper-C?

Today the pharmaceutical industry demands ever greater effectiveness, faster turnaround times, and lower costs, despite having to process massive amounts of data. In response to such uncompromising demands, effective handling of big data has become key for the next step of drug development.

Hyper-C is our revolutionary in-silico platform powered by sophisticated algorithms for drug discovery and development. Over 70 man-years of development time have been invested into Hyper-C’s creation to make it one of the most powerful platforms for identifying undetected relationships between drug candidates and diseases at a molecular level. Allowing pharmaceutical companies to create innovative treatments that hit the market faster than ever before and helping patients in dire need of novel and effective treatments in under-researched rare diseases to get help currently unavailable to them.

Development

The Hyper-C Drug Discovery Process

Hyper-C extracts biomedical data from numerous sources such as scientific literature, clinical trials, patents, Omics datasets, and dedicated biomedical databases and organizes these vast and different data sources into structured form. These structured data form the basis for modeling disease pathophysiology as well as drug mechanism of action on the molecular level. Drug repositioning candidates are identified via network alignment algorithms thus matching drug mechanism of action with disease pathophysiology.

The Hyper-C process in a nutshell:

Harvest biomedical data from 20+ major data sources such as scientific literature, clinical trials, Omics datasets, patents, and dedicated biomedical databases.

Generate network-based molecular models of disease pathophysiology and drug mechanism of action.

Identify beneficial drug-disease-matches via network alignment algorithms.

Propose novel indications for indication expansion based on the interference of disease pathophysiology and drug mechanism of action.

Propose drug leads for further development based on the interference of disease pathophysiology and drug mechanism of action.

Propose biomarker candidates at the interference of disease pathophysiology and drug mechanism of action supporting further preclinical and clinical drug development.

Analyze proposed drug candidates and indication expansion opportunities in terms of business and IP perspectives.

The Advantages of Hyper-C

Hyper-C is a very effective tool to detect relationships between drugs and diseases that would otherwise remain buried in the universe of available biomedical data. The full potential of Hyper-C is unlocked within Delta4 resulting in the following key benefits:

Reduced discovery and development time drastically
Increased probability of success by combining proprietary algorithms with drugs that have known safety profiles
Increased drug discovery efficiency via drug repurposing
Provision of clear mechanism of action hypotheses supporting regulatory requirements
Provision of biomarker candidates for stratification leading to more efficient testing in clinical trials

Our Partners & Clients

At 4P-Pharma, our foundation is based on scientific rationale. Delta4 has provided us with this essential foundation for our co-development project, enabling us to start from the mechanism of action in the disease. This approach allows us to more accurately and quickly identify and validate therapeutic targets, making our drug development process more efficient and focused.

The Delta4 team members are highly competent in big data network analyses both from the disease side and from the drug product and pharmacology side. Their methodology of marrying one with the other led us to new intellectual property.

This innovative methodology has enabled us to identify therapeutic targets that have never been described before for specific indications.

Thanks to DELTA4, we have been able to speed up the selection of preclinical models, that will allow us to effectively prove the beneficial effects of those drug candidates.

Their reporting is thorough and to the point. We highly recommend Delta4 as an AI partner for drug discovery and development.

...allowing us to progress in bringing new drugs to patients suffering from serious, untreated diseases.

Previous

Next

Proud Member of Scientist.com

Streamlining Transparency and Cooperation

Scientist.com provides a unique platform where researchers and suppliers can both find each other and work together more easily. They provide a collaboration framework to streamline the typically long and tedious process of defining the terms and conditions of an agreement.
Members can work together smoothly and effortlessly by agreeing to the rules of the platform. The result is that together we can achieve the results we need faster.

“Delta4’s AI-Powered Hyper-C Platform Uncovers New Drug Indications, Expanding Treatment Potential for Iguratimod” – As Featured on Scientist.com

Are you a member of Scientist.com? View Our Profile

Get Involved

Learn how you can contribute to the exciting work happening at Delta4

Careers

Forging the innovative treatments of the future requires brilliant minds and we’re always on the lookout for talent.

Investors

Contact us to find out more about how you can invest with us and be a part of pioneering the next successful treatment.

Medical Community

Learn how you can partner with us and combine our technology with your knowledge to develop treatments faster.